Mesoblast (ASX:MSB) onboarded ten transplant centers in the US for the supply of Ryoncil for the treatment of steroid-refractory acute graft versus host disease during the March quarter, and the firm plans to recruit ten more priority transplant centers during the June quarter, according to a Wednesday Australian bourse filing.
The firm brought on board a team of nine key account managers in the last week of April, who will focus on onboarding the remaining 35 priority transplant centers, accounting for 80% of US pediatric transplants.
It also secured a Type B meeting with the US Food and Drug Administration scheduled for the June quarter to discuss the accelerated approval pathway for Revascor, a candidate for the treatment of patients with ischemic chronic heart failure with reduced ejection fraction and inflammation.
Its shares fell 2% in recent trading on Wednesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.